Zeke Capital Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Zeke Capital Advisors’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$46.9K	Hold	15,633	–	–	﹤0.01%	464
2022 Q3	$85K	Hold	15,633	–	–	0.01%	451
2022 Q2	$70K	Hold	15,633	–	–	﹤0.01%	467
2022 Q1	$139K	Hold	15,633	–	–	0.01%	496
2021 Q4	$138K	Hold	15,633	–	–	0.01%	298
2021 Q3	$178K	Hold	15,633	–	–	0.01%	282
2021 Q2	$263K	Buy	15,633 +12,500	+399%	+$368K	0.02%	259
2021 Q1	$113K	Hold	3,133	–	–	0.01%	293
2020 Q4	$130K	Buy	+3,133	New	+$159K	0.01%	281

Other funds holding IKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $246M AUM 27.83% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Zeke Capital Advisors's IKT Position: Q4 2022 in Review

Zeke Capital Advisors held its Inhibikase Therapeutics (IKT) position steady in Q4 2022 at 15,633 shares worth $46.9K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Zeke Capital Advisors first reported a position in IKT in Q4 2020 and has held it in 9 quarters since. The position peaked at $263K in Q2 2021. 19 funds tracked by Wall St. Rank hold IKT as of Q4 2022.

Zeke Capital Advisors held 15,633 shares of Inhibikase Therapeutics worth $46.9K as of Q4 2022.
Zeke Capital Advisors left its Inhibikase Therapeutics share count unchanged in Q4 2022.
Inhibikase Therapeutics made up ﹤0.01% of Zeke Capital Advisors's portfolio in Q4 2022, its #464 holding.
Zeke Capital Advisors first reported a position in Inhibikase Therapeutics in Q4 2020 and has held it in 9 quarters since.
Zeke Capital Advisors's Inhibikase Therapeutics position peaked at $263K in Q2 2021.
19 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.